Sales licenses of Agrylin & Effient transferred to respective Shire & Daiichi Sankyo
In the 2nd half of the year, selling companies of the essential thrombocytosis therapy, ‘Agrylin’ and the antithrombotic therapy, ‘Effient,’ will be changed.
So far, Agrylin and Effient were sold by Yuhan Corporation and jointly Lilly Korea and Daiichi Sankyo Korea, respectively.
According to t...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
